Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:4/14/2009

VIENNA, Va., April 14 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI Corporation (NYSE AMEX: CVM) to its shareholders:

Dear Fellow Shareholders:

A very important event has just transpired for our company. Dendreon Corporation has announced that its pivotal Phase III trial with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control. The full data from the 512 patient study will be presented on April 28 at the American Urological Association conference.

The significance of Dendreon's success to CEL-SCI is great. For years most investors have shunned the cancer immunotherapy space because of the many failures of various companies involved in the space. While we at CEL-SCI have always tried to differentiate why our immunotherapy approach to treating cancer should be successful where other immunotherapy approaches have failed, the whole cancer immunotherapy space has been so tainted that it was almost impossible to be heard. The successful outcome of the Dendreon study gives the cancer immunotherapy field the needed validation to attract new money to the space. The success of Dendreon proves that it is possible to harness the human immune system against a patient's own cancer.

Geert Kersten, CEO of CEL-SCI said, "We believe that the success of Dendreon validates the cancer immunotherapy area as a promising alternative/adjunct to existing cancer therapies and think that it could lead to enhanced opportunities for CEL-SCI in both the investment and scientific communities."

About CEL-SCI's Phase III Cancer Drug Multikine:

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half ye
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., LAS ANGELES, December 2 /PRNewswire-FirstC...announced today that it would initiate a programme...informed of the significant,progress which Fountai..., as,well as to provide shareholders with regular ...n Capital Partners and others. , Fountain...
(Date:12/2/2009)... TAMPA, Fla., Dec. 2 Laser Spine ... spinal surgery, is pleased to announce a partner...an extensive six-month negotiation and clinical re... healthcare provider of minimally invasive spinal ...ffective immediately, patients with United Healthc...
(Date:12/2/2009)..., ROYAL OAK, Mich., Dec. 2 ALERT ... company today announced the exclusive availabili...rs. Designed to look like a piece of jewelry, thes...cal function; immediate emergency medical response.../cgi-bin/prnh/20091202/DE19790 ) ,, For elderl...
Breaking Medicine Technology:Fountain Healthy Aging Inc Business Update For Shareholders 2Fountain Healthy Aging Inc Business Update For Shareholders 3Laser Spine Institute Partners with United Healthcare 2Laser Spine Institute Partners with United Healthcare 3Scientists should look at their own carbon footprint 8743 1Scientists should look at their own carbon footprint 8743 2Automated Artificial Pancreas Controls Blood Glucose Levels in Diabetes Patients for First Time 48181 1Automated Artificial Pancreas Controls Blood Glucose Levels in Diabetes Patients for First Time 48181 2Automated Artificial Pancreas Controls Blood Glucose Levels in Diabetes Patients for First Time 48181 3Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 1Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 2
...19 Results from a Phase III,clinical trial evalua...,once monthly for the treatment of postmenopausal ...y for Bone and Mineral Research (ASBMR),29th Annua...risedronate 150,mg once monthly to risedronate 5 m...increases in bone mineral density (BMD) were simil...
.... 18 A long-term study found,that a type of stem ...ening,diseases, such as leukemia and lymphoma, res... recipients. Further, males are likely to recover,...of female patients,remains compromised. In additio...ors regained levels of sexual activity and functio...
Other Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 2Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 3Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 4
(Date:12/2/2009)...GINIA BEACH, Va., Dec. 2 By now, m...okeless cigarettes continue to grow in popularity....lable at the PremiumEcigarette - the new single pi... - at the amazingly low price of $14.99. ,, "Th... the e-cigarette at a very low price, before makin...
(Date:12/2/2009)... , New Directors Represent Diverse Healthc...wswire-USNewswire/ -- The membership of the Nation... its Board of Directors and reappointed four curre...a wide range of healthcare stakeholders, including...nd public and community healthcare. ,, The new...
(Date:12/2/2009)...LADELPHIA, Dec. 2 Independence Blu...its contract with Lincoln Financial Group. IBC wil...approximately 10,000 Lincoln Financial Group emplo...tion. The Lincoln plan offerings will include the ...,, "I know I speak for all of us at Independenc...
(Date:12/2/2009)...lif.Researchers from the California Institute of T...il, and for the first time, the previously mysteri...ed ubiquitin are added by enzymes called ubiquitin...Ubiquitin chains tag target proteins for destructi... "We found that ubiquitin ligases build ubiquitin ...
(Date:12/2/2009)...is the official congress of the European Associati...of the European Society of Cardiology, where techn...resented. , New case reports will be presented ...highlighting the role of this new technology. , ...iques, it is likely that non-invasive imaging will...
Breaking Medicine News(10 mins):Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2Health News:National Quality Forum Members Elect Nine Directors to Board 2Health News:National Quality Forum Members Elect Nine Directors to Board 3Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 2Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 3Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 4Health News:Media alert: EUROECHO 2009 2
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ...roducts and services, today announced that it will...nded September 27, 2008 after the,market close on ... Time) to discuss its second quarter results,and c...
...28 Professional Healthcare,Resources, Inc., one o...healthcare agencies based in the Washington, DC me...been named to the 2008 Homecare Elite. The,selecti...ealthcare publisher., This annual review identifi...
...ialty Pharmacy programs expand URAC,s Pharmacy,Qua...28 URAC announced that four,companies have achiev...ograms under its Pharmacy Quality Management(SM) i...his scope for the pharmacy benefit management and ...
...tion in BRCA1 Mutation Carriers , One X chromoso...romosome in women who carry mutations in the BRCA1... with a later onset of breast or ovarian cancer in...X chromosome, the cells in a woman,s body inactiva...
...-lowering statins is associated with a statistical...n (PSA) levels, according to a report in the Octob... Cancer Institute . , Previous studies examined w... association between statins and PSA level. , In...
...patients in more than 1,500 physician practices ha...ealth-care experiences, with minority patients hav...dings suggest that while all doctors should be att...nt-centered. The study, which was led by a health ...
Other Medicine News:Health News:ATS Medical Announces Third Quarter 2008 Earnings Release Date and Conference Call 2Health News:Professional Healthcare Ranked Among the Top 25 Percent of Home Health Care Providers in the Country for 2008 2Health News:Professional Healthcare Ranked Among the Top 25 Percent of Home Health Care Providers in the Country for 2008 3Health News:Four Companies Are First to Achieve Accreditation Under Two New URAC Pharmacy Quality Management(SM) Programs 2Health News:Also in the Oct. 28 JNCI 2Health News:Also in the Oct. 28 JNCI 3Health News:Also in the Oct. 28 JNCI 4Health News:Also in the Oct. 28 JNCI 5Health News:Statin use associated with reduction in prostate specific antigen levels 2Health News:Racial and ethnic disparities detected in patient experiences 2
Snap-In Snap-Out®-II Alligator Grasping Forceps Insert
Snap-In Snap-Out®-II Strong Grasping Forceps Insert
Optima III 45 Noninsulated Maryland Dissector
Dolphin-Nose Dissector, dual-incision
Medicine Products: